Edwards Lifesciences EW
Healthcare · Medical - Devices · Synthos Deep Dive · 2026-07-03
The Overview
Edwards makes replacement heart valves and repair devices that cardiologists implant through a catheter (a thin tube threaded up to the heart) instead of open-heart surgery. Its flagship product line, SAPIEN TAVR, is the market leader for replacing a failing aortic valve. It is a high-quality, focused business — very profitable, with more cash than debt.
The catch: the stock is expensive relative to how fast the company is growing. You are paying roughly 50 dollars of stock price for every 1 dollar of last year's profit, but the business is only growing sales about 10% a year. Great company, full price. Our verdict is Watch — a name to keep on the list and buy on a pullback, not chase at today's price near its high.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit above middle). The company itself is financially sturdy (more cash than debt, steady demand). The risk is the price — it's high, so a stumble would hurt, and the stock already fell about 28% at one point in the past year.
- Growth Quality 6/10 (good, not elite). Growing steadily and very profitable, but growth is slowing, not speeding up.
- Exponential Potential 4/10 (moderate-low). A solid grower, but it's already a $54 billion company in a defined niche — don't expect it to multiply quickly.
The one big worry: you are paying a premium price for modest growth. If aortic-valve or mitral/tricuspid sales slow, or a competitor takes share, the stock's rich valuation can drop fast even if the business is fine.
Putting a number on it: our fair-value estimate is $90 against a current price of $90.21 — a premium price for a business we still like.
Our summary metrics
Net-cash balance sheet & 0.87 beta, but 50× trailing EPS on a ~10% grower and a 28% drawdown in the last year.
~10% forward revenue / ~12% EPS CAGR, 78% gross margin, mid-teens ROIC — good, not elite; growth decelerating.
Focused structural-heart pure-play with a real TAM, but a $54B cap and single-digit-to-low-teens growth cap the multibagger.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Focused structural-heart pure-play with a real TAM, but a $54B cap and single-digit-to-low-teens growth cap the multibagger.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $97.45 (high $110 / low $85; 32 Buy · 16 Hold · 0 Sell) — context, not our anchor |
| Valuation | ~50× trailing EPS · 31× FY26E · 28× FY27E · 21× FY30E · EV/S 8.3× · EV/EBITDA 37× |
| Technicals | Near 52-wk high ($94.37), above 50/200-DMA, but RSI 74 (overbought) and a −28% max drawdown in the trailing year |
| Conviction | Low — 0 net-bullish voices, 0 traceable KB claims; call rests entirely on the data |
| Position sizing | If owned, a small ~1–2% quality-satellite; no basis for a core weight here |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for EW — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $90.21, 1% above the 50-day average ($89), 6% above the 200-day average ($85) — an uptrend. 5% below the 52-week high of $95, 24% above the 52-week low of $73.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $90.21 is currently inside the band (band $88–$93).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 52.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.20, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = EW · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Edwards Lifesciences (NYSE: EW) is a ~$54B pure-play structural heart medical-device company, founded 1958, headquartered in Irvine, CA. After divesting its Critical Care patient-monitoring business in 2024 (the source of the one-off gain that inflated FY24 GAAP EPS to $6.98), Edwards is now a focused structural-heart franchise in three lines: transcatheter aortic valve replacement (TAVR / SAPIEN), transcatheter mitral & tricuspid therapies (TMTT / PASCAL, EVOQUE, SAPIEN M3), and surgical structural-heart valves (INSPIRIS, RESILIA, KONECT). Fiscal year ends December 31.
Revenue mix (FY2025, from FMP product segmentation):
- By product: Transcatheter Heart Valves (TAVR) $4.49B (74%) · Surgical Heart Valve Therapy $1.03B (17%) · Transcatheter Mitral & Tricuspid (TMTT) $0.55B (9%). TAVR is the engine; TMTT is the small, fast-growing option; surgical is the mature base.
- By geography: United States $3.54B (58%) · Europe $1.52B (25%) · Rest of World $0.65B · Japan $0.35B. US-centric but meaningfully international.
The strategic story is (a) defend and extend TAVR — the EARLY TAVR data pushing treatment of earlier-stage and asymptomatic aortic-stenosis patients, expanding the eligible pool; and (b) scale TMTT — mitral/tricuspid repair and replacement (EVOQUE, PASCAL, SAPIEN M3) as the next growth leg off a small base.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of EW in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0. No investor or operator in our tracked panel has published a distilled, traceable claim on Edwards. That is an honest gap, not a hidden signal — structural-heart med-tech simply is not where our net-bullish voices concentrate.
What this means for the verdict: every judgment below is derived from the fundamentals (FMP filings), the analyst-estimate consensus, and the quant/technical block — not from conviction we cannot source. We will not manufacture a thesis. When expert coverage exists we cite real claim_ids inline; here there are none to cite, and we say so plainly. Treat this note as a fundamentals-and-quant read, and weight it accordingly against names where a broad expert panel corroborates the numbers.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Balance sheet is a fortress (net cash ~$2.2B, net-debt/EBITDA −1.2×, beta 0.87), but ~50× trailing EPS on a ~10% top-line grower and a −28% trailing-year drawdown mean valuation, not solvency, is the risk. |
| Growth Quality | 6 · Good | ~10% forward revenue CAGR, ~12% EPS CAGR, 78% gross margin, ROIC ~12% and ROE ~11% — a durable, well-run compounder, but returns and growth are good rather than elite, and both are decelerating. |
| Exponential Potential | 4 · Moderate-Low | Real TAM in structural heart and a fast-growing TMTT option, but a $54B cap plus single-digit-to-low-teens growth caps the multibagger. Not a small accelerating name. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | EARLY TAVR / asymptomatic expansion re-accelerates TAVR; TMTT (EVOQUE, PASCAL, SAPIEN M3) inflects; FY27E EPS beats to ~$3.55 (vs $3.38 cons); premium multiple holds ~33×. | ~$116 (+23%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS $3.38; a mid-teens-return structural-heart leader earns a ~27× multiple as growth normalizes. | ~$90 (−5%) |
| Bear | TAVR share loss (new entrant / CMS NCD disappoints) or TMTT ramp stalls; FY27E EPS misses to ~$3.10; multiple de-rates to ~21× as the market re-rates a ~10% grower. | ~$66 (−30%) |
Synthos fair value = the base case, ~$90 (−5%), with the full $66–$116 span as the honest range. This anchor sits below the Street's $97.45 consensus — we are less willing than the sell side to pay up for ~10% growth at ~50× trailing. Our bull ($116) is above the Street's $110 high; our bear ($66) is below the $85 low, because we take multiple-compression risk on a richly-priced name seriously. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). EW is a quality compounder, not an exponential:
- Forward growth: revenue CAGR FY25→FY30E ~10.1% ($6.07B → $9.79B est); EPS CAGR (on estimates) FY25 $2.60 → FY30E $4.59 ≈ ~12%. Solid, not explosive.
- Acceleration (the 2nd derivative) is negative: consensus EPS growth runs ~+16% (FY26E) → +12% (FY27E) → +12% (FY28E) → +12% (FY29E) → +8% (FY30E). Revenue guidance itself (FY26 constant-currency 9–11%) is a step down from the divestiture-era growth rates. The business is a steady decelerating compounder, not an accelerant.
- Room to run: the structural-heart TAM is genuinely large and under-penetrated (asymptomatic aortic stenosis and the mitral/tricuspid opportunity are real), so demand runway exists. But at $54B with ~10% growth, a 3× from here would imply a ~$160B structural-heart pure-play — a stretch on this growth rate.
- Reinvestment runway: disciplined — R&D ~17% of sales, modest capex (~4% of sales), FCF ~$1.3B FY25. Capital returns skew to buybacks ($500M ASR completed in Q1'26, ~$1.5B remaining authorization); no dividend.
Exponential Potential: Moderate-Low (4/10). Own EW, if at all, for durable low-teens earnings compounding at a fair-to-full price — not for a fast multibagger. A $5B name with these margins and an accelerating TMTT would score far higher; a $54B decelerator does not.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $6.07B, +11.5% (FY24 continuing $5.44B). Q1'26 $1.65B, +16.7% reported / +12.7% constant-currency. Steady low-double-digit top line.
- Quarterly trajectory: Q1'25 $1.41B → Q2 $1.53B → Q3 $1.55B → Q4 $1.57B → Q1'26 $1.65B (+16.7% YoY). Consistent, seasonal, no acceleration.
- Margins: gross 78.0% TTM (management guides FY26 gross 78–79%), operating ~28–29% (31.4% adjusted Q1'26), net 17.3% TTM. Elite gross margin; solid operating margin.
- Earnings: FY25 net income (continuing) $1.07B, EPS $1.84 GAAP / ~$2.60 adjusted-basis. Caution: FY24 GAAP EPS of $6.98 is not comparable — it includes a ~$2.77B one-off gain from the Critical Care divestiture. Use continuing-ops / adjusted figures. Q1'26 GAAP EPS $0.66, adjusted $0.78.
- Cash flow: operating CF ~$1.60B FY25, capex ~−$0.26B, FCF ~$1.34B — high-quality, ~80% FCF conversion of operating cash.
- Balance sheet: net cash — cash & short-term investments $4.23B vs total debt $0.71B, net debt −$2.23B, net-debt/EBITDA −1.2×, current ratio 4.4×. About as clean as a med-tech balance sheet gets.
6. Valuation — priced in or room?
There is no way to call EW cheap: ~50× trailing EPS, 8.3× EV/sales, 37× EV/EBITDA, price/book 5.3×. FMP's letter rating (B+) flags exactly this — strong ROE/ROA/DCF scores but a price-to-earnings score of 1/5 (the weakest possible). The bull's defense is that EPS out-grows the multiple: on consensus the forward P/E compresses to 31× (FY26E) → 28× (FY27E) → 21× (FY30E) — but that de-rating requires ~12% EPS growth to actually show up for five straight years, with no competitive stumble. A ~10% grower does not obviously deserve a ~30× forward multiple; the PEG is unflattering (forward PEG ~4× on the TTM ratios block). Street targets (context): consensus $97.45, high $110, low $85 — our $90 base fair value is below consensus because we are unwilling to underwrite multiple persistence at this growth rate. Not a value buy; a quality-at-a-full-price name best entered on weakness.
7. Technicals (from the FMP tech block)
- Trend: up. $94.37 sits above the 50-DMA ($85.23) and 200-DMA ($82.45), 50 above 200 (golden-cross posture). MACD +2.0 (positive).
- Location: at the 52-week high ($94.37), +29.9% off the 52-week low ($72.65) — but note a −27.8% max drawdown within the trailing year, so this is a name that has swung hard.
- Momentum: RSI(14) 73.8 — overbought (>70). This is a stretched-entry warning: buying at a 52-week high with RSI in the mid-70s is a poor risk/reward entry.
- Relative strength: EW +22.3% 12-mo vs SPY +20.6% — roughly in line with the market, and behind QQQ +30.3%. 3-mo +16.1% vs SPY +13.7%. Recent outperformance, but not persistent category leadership.
- Read: the trend is constructive but the entry is not — overbought, at the high, after a sharp prior drawdown. Technicals argue for patience, consistent with the Watch verdict: wait for a pullback toward the rising 50-DMA (~$85).
8. Moat & competitive position
Edwards' moat is real but narrower than a diversified pharma's: (1) category leadership in TAVR — SAPIEN is the reference transcatheter aortic valve, with a deep clinical-evidence base (EARLY TAVR, PROGRESS, 10-year COMMENCE durability data) that raises the barrier for challengers; (2) a focused R&D + clinical-trial engine in structural heart that competitors must match trial-by-trial; (3) switching costs / physician training around its platforms. The frame is an oligopoly: TAVR is effectively Edwards vs Medtronic (and Boston Scientific historically), and Q1'26 noted a competitor exiting Europe — a share tailwind. The risks are new TAVR entrants, the pending CMS National Coverage Determination reconsideration (could help or hurt access), and execution on the still-small TMTT ramp.
Peer set (FMP-supplied, market cap): these are broad MedTech/health peers rather than direct structural-heart comps — Boston/Medtronic are the true competitors and are not in this list. Agilent $37B, Alcon $34B, argenx $58B, Becton Dickinson $57B, Bruker $9B, Cardinal Health $56B, DexCom $27B, Haleon $43B, STERIS $21B, Veeva $31B. EW's 78% gross margin and net-cash balance sheet screen at the high-quality end of this group; its ~50× P/E is also at the rich end.
9. Management, capital allocation & guidance
- Capital allocation: shareholder-friendly and disciplined — $500M accelerated share repurchase completed in Q1'26 with ~$1.5B remaining authorization; no dividend; modest capex (~4% of sales); net-cash balance sheet. R&D held near ~17% of sales.
- Insider activity: the sampled window (May–June 2026) shows routine officer sales — CEO Bernard Zovighian (523 sh @ $87.92, 2026-06-17), and several CVP/controller-level Rule-10b5-1-style dispositions. Normal diversification at elevated prices; no accumulation, but no alarming discretionary cluster either.
- Management's own guidance (the earnings-release track, half-weighted — they talk their own book): In the Q1'26 release (2026-04-23), management raised FY2026 guidance: constant-currency sales growth to 9–11% (from 8–10%); adjusted EPS to $2.95–$3.05 (midpoint raised); TAVR sales growth to 7–9%; gross margin 78–79%; operating margin at the high end of 28–29% (≈150 bps of constant-currency expansion); R&D ~17% of sales. Pipeline milestones flagged: next-gen PASCAL and US tricuspid PASCAL launches in Q4, SAPIEN M3 US ramp, TRIFORMIS surgical tricuspid in 2H, PROGRESS trial data at TCT. This is management's self-interested framing, weighted accordingly — but it corroborates the ~10% top-line / low-teens EPS picture the estimates imply.
10. Catalysts & what to watch
- Next earnings: 2026-07-23 (Q2'26; Street EPS $0.73, revenue ~$1.70B). Watch TAVR constant-currency growth and the TMTT ramp rate — the two swing factors.
- CMS National Coverage Determination reconsideration for TAVR — could expand or constrain US access; a genuine binary.
- PROGRESS trial (moderate aortic stenosis) data at TCT (later 2026) — potential TAVR TAM expansion.
- TMTT launches: next-gen PASCAL (Q4), US tricuspid PASCAL (Q4), SAPIEN M3 US uptake, TRIFORMIS (2H) — the growth-reacceleration levers.
- Competitive: new TAVR entrants / share shifts (the noted European competitor exit was a tailwind; watch for reversals).
Thesis tripwires (what would change the call): two consecutive quarters of TAVR constant-currency deceleration below high-single-digits; a TMTT ramp that stalls; an adverse CMS NCD; or a multiple re-rating that takes the stock toward our bull entry (~$85 area), which would improve the risk/reward and could move this to Buy.
11. Key risks
- Valuation / de-rating (the primary risk): ~50× trailing / 31× forward EPS on a ~10% grower leaves no margin for a demand or competitive disappointment. This is a multiple-compression story, not a solvency one.
- Single-franchise concentration: ~74% of revenue is TAVR. Any aortic-valve share loss or reimbursement setback hits the whole company.
- Competitive entry: TAVR and TMTT are attractive, well-capitalized-competitor markets (Medtronic, Boston Scientific, Abbott); a next-gen entrant could pressure price or share.
- Regulatory / reimbursement: the CMS NCD reconsideration and ex-US coverage guidelines directly gate procedure volumes.
- Execution on TMTT: the next growth leg is still small ($0.55B) and depends on launches landing on schedule.
- No expert corroboration: unlike our conviction-track names, no tracked expert panel independently validates the thesis — the call rests on the data alone.
12. Verdict, position sizing & monitoring
Watch. Edwards is a genuinely high-quality, focused structural-heart franchise — 78% gross margin, net-cash balance sheet, FCF ~$1.3B, category leadership in TAVR, and a real (if slow-ramping) TMTT option. But the fundamentals and the estimates describe a ~10% revenue / low-teens EPS compounder, and at ~50× trailing / 31× forward EPS, near a 52-week high with RSI in the mid-70s, the price already reflects the quality. Our base-case fair value (~$90) sits slightly below both the current price and Street consensus. There is no expert-panel conviction here to override the quant read.
- Sizing: not a core position at this price. If owned, a small ~1–2% quality satellite, ideally initiated on a pullback toward the rising 50-DMA (~$85) or lower — where the risk/reward flips toward Buy.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. A meaningful de-rate or a TMTT/TAVR re-acceleration would move this to Buy — Tactical.
- Single biggest risk: paying a premium multiple for modest, decelerating growth — the de-rating risk is the whole call. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $94.37.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — no expert coverage of EW in the Synthos knowledge base. The verdict is fundamentals- and quant-driven; no conviction is claimed or fabricated (claim-ID reconciliation makes fabrication structurally impossible — there are simply no claims to cite).
- Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the 2026-04-23 Q1'26 SEC 8-K earnings release. Forward figures are analyst consensus (FMP), labeled as estimates.
- Comparability caveat: FY24 GAAP EPS ($6.98) includes a one-off ~$2.77B Critical Care divestiture gain and is not representative of run-rate earnings; use continuing-ops / adjusted figures.
- Management caveat: the raised FY26 guidance in §9 is management's own book, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").